Singapore: HSA issues several retail-level recalls of therapeutic products and Chinese proprietary medicines in breach of applicable regulations

In brief

In the month of August 2022, the Health Sciences Authority (HSA) issued several retail-level recalls in respect of therapeutic products and Chinese proprietary medicines that were in breach of applicable healthcare regulations.


Key takeaways

  • Sellers and suppliers should note that health products must be in line with applicable healthcare regulations.
  • Anyone found to have supplied therapeutic products that are adulterated may be imprisoned for up to three years and/or fined up to SGD 100,000 upon conviction.
  • Anyone found to have supplied Chinese proprietary medicines that are adulterated may be imprisoned for up to two years and/or fined up to SGD 5,000 upon conviction.  

In more detail

In August 2022, the HSA issued product recalls in relation to the following products:

  • Apo-Acyclovir Tablet 800mg Tablets, as such tablets was found to contain impurities above the acceptable level
  • Lorazepam Injection 4mg/ml, as out-of-specification results were observed during testing of samples for the affected batch
  • GINCARE-60 Film Coated Tablet 銀之杏60, due to the detection of ibuprofen, a prohibited substance

Hospitals, clinics and retail and wholesale suppliers have been instructed to stop supplying the affected batches of such products and to return the remaining stocks to the respective companies.  

* * * * *


© 2022 Baker & McKenzie.Wong & Leow. All rights reserved. Baker & McKenzie.Wong & Leow is incorporated with limited liability and is a member firm of Baker & McKenzie International, a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a "principal" means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an "office" means an office of any such law firm. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.

Copyright © 2024 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.